Shire Sees Future For Premature Baby Drug Despite PhII Disappointment
Executive Summary
Shire's product candidate for a rare eye disease in premature infants has failed in a Phase II study, but secondary endpoint data suggest SHP607 might still have a future.
You may also be interested in...
Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.
Shire buys Premacure for infant eye treatment
Shire said it acquired Premacure, a closely held Swedish biotechnology company developing a treatment for a rare disease that can blind babies.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.